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Abstract We report a child with a severe choreadystonic
movement disorder, bilateral periventricular nodular heter-
otopia (BPNH), and secondary microcephaly based on
compound heterozygosity for two new ARFGEF2 mutations
(c.2031_2038dup and c.3798_3802del), changing the limited
knowledge about the phenotype. The brain MRI shows
bilateral hyperintensity of the putamen, BPNH, and gener-
alized atrophy. Loss of ARFGEF2 function affects vesicle
trafficking, proliferation/apoptosis, and neurotransmitter re-
ceptor function. This can explain BPNH and microcephaly.
We hypothesize that the movement disorder and the
preferential damage to the basal ganglia, specifically to the
putamen, may be caused by an increased sensitivity to
degeneration, a dynamic dysfunction due to neurotransmitter





In 2004 mutations in the gene ARFGEF2 encoding ADP-
ribosylation factor guanine nucleotide exchange factor 2,
were found to cause autosomal recessive bilateral periven-
tricular nodular heterotopia (BPNH) in four patients from
two Turkish pedigrees [1]. Clinical features reported were
microcephaly, feeding difficulties, severe mental retarda-
tion, quadriparesis, and epilepsy. More details on the
phenotype were not reported and since then, to our
knowledge, no additional patients have been published.
We discuss a patient with a different phenotype caused by
two new ARFGEF2 mutations.
Case
Our patient is the only child of non-consanguineous parents
from Dutch descent. Prenatal ultrasounds showed growth
retardation. She was born at 38 weeks of gestation with an
Apgar score of 10 after 5 min, birth weight 2,790 g, and
length 46 cm. Occipito-frontal circumference was 34.2 cm
at the age of 3 weeks (−1.5 SD). During the first year
developmental delay became apparent. She showed social
smiling at 2 months and grasping at 5 months, and rolled
over at the age of 8 months. There were excessive
extension movements. She had persistent feeding problems,
severe drooling, and frequent vomiting. At the age of
9 months a pediatrician noted dystonic-spastic paraplegia
with axial hypotonia. With physical therapy she showed
some progression, but did not reach normal milestones. At
the age of 4 years feeding difficulties prompted a gastro-
stomy. Despite adequate caloric intake, growth is unsatis-
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Rotterdam, the Netherlandsto 0.5 cm below the –2.5 SD curve. She never had
seizures. Now, at the age of 7 years, she makes eye contact,
smiles, and understands some words. She vocalizes, but does
not produce anywords.Pupillaryresponses are normal. There
is no nystagmus. Axial muscle tone is low and variable in the
extremities. Muscle strength is normal. She shows a severe
extrapyramidal movement disorder with irregular repetitive
jerkingmovementsofallextremitiesandtheface(chorea)and
sustained abnormal movements and posturing (dystonia).
This is exacerbated by emotions and during infections when
large proximal jerking movements may resemble ballism.
There is no rigidity or ataxia. Tendon reflexes are lively and
symmetric, with extensor plantar responses (Babinski sign).
She can sit with support, but cannot stand. The movement
unrest can be so severe that she becomes exhausted and is
partially responsive to treatment with high doses of benzo-
diazepines.
Brain MRI at the age of 13 months showed BPNH,
myelination delay, and generalized atrophy, a second MRI at
age 4 years and 10 months showed improved myelination,
stable or minimally progressive generalized atrophy but also
symmetric atrophy of the basal ganglia, specifically of the
globus pallidus and the putamen with focal T2-hyperintensity
of the putamen (Fig. 1). In retrospect, inhomogeneous
abnormalities of the putamen can also be seen on the first
MRI and suggest early degeneration resulting in gliosis.
EEGs show delta-activity without differentiation or epilep-
tiform activity. Metabolic testing of urine and plasma,
including amino acids, lactate, pyruvate, and creatine kinase
was normal. The family history is unremarkable.
Sequence analysis of all 39 coding exons and intron–exon
boundaries of the ARFGEF2 gene on chromosome 20 shows
compound heterozygosity for two variations that have not
been previously reported. At the DNA level c.2031_2038dup
and c.3798_3802del using reference sequence NM_006420.2
and at protein level p.Gln680ProfsX2 and p.Phe1267-
GlyfsX17, respectively. Both these variations lead to frame
shift followed by a premature stop-codon and are therefore
considered pathogenic mutations. Parents are heterozygote
for found mutations (Fig. 2).
Discussion
Mutations in ARFGEF2 can cause autosomal recessive
bilateral periventricular nodular heterotopia (BPNH) with
microcephaly [1]. Our patient shows that a choreadystonic
extrapyramidal movement disorder can be part of the
phenotype. The movement disorder is reflected in MRI
abnormalities of the basal ganglia, specifically of the
putamen, in addition to generalized atrophy and BPNH.
Anatomically, putamen and caudate nucleus form the dorsal
striatum and are the major afferent center of the basal
ganglia, receiving excitatory input from the cerebral cortex,
Fig. 1 Brain MRI made at the
age of 13 months (images A, B,
and C) and at the age of 4 years
and 10 months (images D, E,a n d
F). A and D T1-weighted images
showing bilateral periventricular
nodular heterotopia with the in-
tensity of gray matter (black
arrow in image D). B and E
T2-weighted images showing
hyperintensity of the putamen
and atrophy of the putamen and
globus pallidus (white arrow in
image E). C and F Flair images,
coronal view, showing bilateral
hyperintensity of the putamen,
more clearly visible on image F
made at a later age (white ar-
row), and mild atrophy of the
hippocampi
334 Neurogenetics (2009) 10:333–336thalamus, and brain stem. The putamen receives projections
from the cortical motor and somatosensory areas, the
midbrain, and the raphe nuclei. The striatum projects to the
globus pallidus and substantia nigra, mainly with GABA-
ergic neurons. Output is mediated by local inhibitory
interneurons [2]. Similar choreadystonic movement disorders
and putamen degeneration on MRI are seen in Huntington’s
disease, Wilson’s disease and Leigh syndrome.
ARFGEF proteinsare guanine nucleotideexchangefactors
(GEFs) that activate ADP-ribosylation factors (ARFs). ARF-
GEF2 protein, also known as BIG2, is one of three GEFs
expressedinthe brainduringthe periodofneuralproliferation
and migration with high expression in the cortical ventricular
zone and ganglionic eminences, the future basal ganglia [1].
ARFs regulate the formation of coated vesicles from the
Golgi, trans-Golgi network (TGN), and endosomes. In
recycling endosomes BIG2 loss of function result in failure
to deliver proteins to the cell membrane [3–5]. This was
shown for the GABA(A) receptor, but also for the transferrin
receptor and the tumor necrosis factor receptor [1, 4, 6, 7].
Other cell surface receptors are likely to be also affected.
To understand our patient’s phenotype, different con-
sequences of ARFGEF2 loss of function need to be
considered. The BPNH are similar to those seen in patients
with loss-of-function mutations in the X-linked filamin A
gene (FLNA). FLNA is the most commonly identified
genetic cause for BPNH, found in approximately one third
of patients [8]. In heterozygous females BPNH is associated
with epilepsy and/or developmental delay or may be an
accidental finding. In males FLNA mutations are often fatal,
but may result in a similar phenotype to affected females
[8, 9]. In both ARFGEF2 and FLNA patients the neuro-
epithelium lining the ventricles is disrupted leading to failed
migration of later-born neurons [9]. The similarity may be
solely due to failed transport of the filamin A protein to the
cell membrane by BIG2 dysfunction or to a final common
pathway disrupting vesicle trafficking [9, 10]. However,
despite the similar brain phenotype, FLNA patients do not
have extrapyramidal movement disorders or microcephaly.
Speculatively, in ARFGEF2 neuronal migration may be
more severely affected due to disruption in GABA(A)
receptor function in the embryonic period, as GABA(A)
antagonists have been shown to impair neuronal motility in
rodents in vitro and in vivo [11, 12].
Microcephaly can be due to diminished neuronal
proliferation and BIG2 inhibition in vitro experiments seem
to suggest this occurs [1]. Increased apoptosis can also cause
microcephaly and atrophy. Other BIG2 inhibition experi-
ments show some signs of endoplasmic reticulum stress in
cultured cells [13]. Possibly, ER stress increases susceptibil-
ity to apoptosis in specific neurons. Our patient’sn o r m a l
occipito-frontal circumference at birth shows that congenital
microcephaly is not obligatory. Why the putamen should
show a specific sensitivity for neuronal loss is unknown.
Finally, ARFGEF2 is expressed postnatally and neuro-
transmitter receptor function can be impaired by defective
exosome function [3, 6]. Disruptions in the recycling of
receptors also hinder dendritic arborization [9]. This may
have contributed to the movement disorder.
Our patient is compound heterozygote for two new
mutations and new patients are needed to determine if a
genotype–phenotype relation exists for ARFGEF2 mutations.
BPNH caused by autosomal recessive ARFGEF2 muta-
tions is more than an anatomical malformation. We suggest
Fig. 2 The sequences of the relevant areas of the ARFGEF2 gene are depicted showing the maternal origin of c.2031_2038dup and the paternal
origin of c.3798_3802del
Neurogenetics (2009) 10:333–336 335that the clinical features of the choreadystonic movement
disorder, BPNH, and microcephaly of our patient can be
understood in the light of abnormal vesicle transport
resulting in neuroependyma disruption, decreased prolifera-
tion of neurons, and/or increased sensitivity to apoptosis and
lifelong exosome dysfunction affecting neurotransmitter
receptor function and neuronal development.
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